Skip to main content
AmigoFish

Treatment Algorithm of Early Relapsed/Refractory Multiple Myeloma (RRMM)

From Oncology Brothers: Practice-Changing Cancer Discussions · · 22 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode of the Oncology Brothers podcast we continued our treatment algorithm series, focusing on early relapsed/refractory multiple myeloma (RRMM). We were joined by Dr. Shaji Kumar, a myeloma specialist from the Mayo Clinic, who shared his insights into current evidence-based treatment strategies for patients whose disease has progressed after frontline therapy.

Key topics discussed included:

- The current standard of care for frontline multiple myeloma, including quadruplet therapy and maintenance strategies

- The role of CAR T-cell therapy and bispecific antibodies, including teclistamab and talquetamab, in early relapsed/refractory multiple myeloma

- Treatment selection based on patient age, prior therapy, drug exposure, and disease biology

- The importance of shared decision-making and incorporating patient preferences into treatment planning

- Recent clinical trial data and emerging therapies shaping the future of multiple myeloma care

This episode provides practical insights into managing early relapsed/refractory disease and navigating today's evolving treatment landscape.

Listen us on:

Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

- X/Twitter: https://x.com/oncbrothers

- ⁠Instagram: https://www.instagram.com/oncbrothers

- Website: https://oncbrothers.com/

Subscribe for more expert discussions on multiple myeloma, hematologic malignancies, cellular therapies, bispecific antibodies, and precision oncology.

#MultipleMyeloma #CART #BispecificAntibodies #Hematology #Oncology

Back to Oncology Brothers: Practice-Changing Cancer Discussions · Report a problem